Achaogen’s plazomicin and levofloxacin safe and effective in treating cUTI, acute pyelonephritis - News-Medical.Net

Achaogen, Inc. also announced today that it has begun dosing in the first-in-human clinical trial of ACHN-975, a first-in-class LpxC inhibitor that is being developed for the treatment of serious infections caused by MDR Gram-negative bacteria ...

Z-Pak Antibiotic Associated with Higher Risk of Heart-Related Death in New Study - Newsinferno.com

The sample size included more than 1.3 million amoxicillin patients—those taking Amoxil, Moxatag, Trimox, Wymox—more than 264,000 people taking Cipro (ciprofloxacin), and another 194,000 patients who were taking Levaquin (levofloxacin), said US News.

Study Links Antibiotic to Slight Rise in Heart Patients' Death Risk - YAHOO!

The sample size included more than 1.3 million patients taking amoxicillin (Amoxil, Moxatag, Trimox, Wymox), more than 264,000 people taking ciprofloxacin (Cipro), and nearly 194,000 patients taking levofloxacin (Levaquin). Another 1.3 million people not ...

Pulmatrix Demonstrates iSPERSE Capabilities for Inhaled Dry Powder Delivery of Antibiotics and Antibodies - Phramalive.com

These results were presented in posters entitled “Formulation Characterization of a Novel Levofloxacin Pulmonary Dry Powder Drug Delivery Technology” and “Development of an iSPERSE™ Based Platform for the Delivery of Macromolecules via Dry Powder ...

FDA Statement regarding azithromycin (Zithromax) and the risk of cardiovascular death - Center for Food Safety and Applied Nutrition

The risks of cardiovascular death associated with levofloxacin treatment were similar to those associated with azithromycin treatment. FDA is reviewing the results from this study and will communicate any new information that results from the FDA review.

Risk of sudden cardiac death may be increased with azithromycin - Examiner

The antibiotic levofloxacin has previously been found to in rare cases cause serious arrhythmias and sudden death. This study has suggested that azithromycin has a similar level of adverse cardiac effects. However, Dr David Juurlink has commented these ...

Achaogen Announces All Objectives Met in Phase 2 Plazomicin Complicated Urinary Tract Infections Study and Start of First-in-Human Study with ACHN-975 - Phramalive.com

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 15, 2012 - Achaogen, Inc. announced today that all objectives were met in the company's multi-national Phase 2 study of plazomicin compared to levofloxacin for the treatment of complicated urinary tract ...

Cempra, Inc. Reports First Quarter 2012 Financial and Operating Results - Yahoo Finance

The study demonstrated that solithromycin's efficacy was comparable to levofloxacin and that solithromycin had a favorable safety and tolerability profile compared to levofloxacin." For the first quarter ended March 31, 2012, Cempra reported a net loss of ...

Sagent Pharmaceuticals Reports First Quarter 2012 Financial Results - Yahoo Finance

Revenue increased 26% to $38.3 million driven by products launched in the last twelve months; Gross profit increased to $5.8 million, or 15.1% of net revenue on strong margins from newly launched products; Launched Midazolam and Levofloxacin in ...

Azithromycin Tied to Increased Risk of Cardiovascular Mortality - Monthly Prescribing Reference

There was a significantly increased risk of cardiovascular death for azithromycin versus ciprofloxacin, but there was no significant difference between azithromycin and levofloxacin. "During five days of azithromycin therapy, there was a small absolute ...